Hints and tips:
...Friday: Nanofilm Technology lists on the Singapore stock exchange, the biggest IPO in the city state in years....
...They can speed up approval and marketing significantly, especially when there is high unmet medical need....
...Medical research shows that the effects on health are much more serious than previously thought, particularly for children, the elderly and expecting mothers....
...Amgen has used off-the-shelf AI from large cloud providers such as Google and Amazon to analyse its previous trial data....
...If UK biotech is to grow further, it needs to come up with a big-selling drug using novel technology to treat a serious disease....
...RainDance Technologies pulled plans for an initial public offering, citing “market conditions”....
...“We are seeing new technologies that are enabling us to target disease like we never have before,” Joe Jimenez, chief executive of Novartis, the biggest European pharmaceuticals group by market capitalisation...
...It went on to license technology designed to kill fat tissues from Harbor-UCLA Medical Center before raising $70m in an IPO in 2012 and a further $90m in 2014....
...Samsung Bioepis, meanwhile, is awaiting European regulatory approval of its own Remicade copy, as well as one based on Enbrel, another arthritis drug co-marketed by Pfizer and Amgen....
...Novartis agreed last week to pay $200m upfront to license the Sting technology from Aduro with a further $500m dependent on success....
...The technology had great promise, but then we realised it would take decades.”...
...The V-280 Valor is in contention for a US military programme, designed to fly twice as fast as the helicopters it could replace....
...Promising UK companies such as Celltech, PowderJect and Cambridge Antibody Technology, have been gobbled up by bigger rivals just as they were hitting their stride....
...However, Mr Hsu and others say the sector is now more mature, with big biotech companies such as Gilead Sciences, Amgen and Biogen producing revenues to rival traditional big pharma, and a new wave of upstarts...
...Shares in Amgen, which is entitled to an 8 per cent royalty on palbociclib sales, dipped 0.3 per cent to $118.82....
...Reaching a medical wing, the robot putters to a stop. A nurse presses its finger scanner, taps in a code and Abbie pops out a drawer with drugs for a patient....
...That in turn has fed a cycle of new medical research and experimentation with many small laboratories gaining funds in an attempt to come up with the next big medical breakthrough....
...Most 3D printers are currently used for building prototypes for the medical, aerospace, engineering and automotive industries, but with advances in digital technology, these machines are becoming smaller...
...Critics of health technology bodies such as Nice argue they have an agenda driven by rationing, which plays down the benefits of new drugs....
...Some biotechs are so big – Celgene, Amgen and Gilead are worth a combined $215bn – they could be mistaken for Big Pharma....
...But consider Amgen, the world’s biggest biotechnology company. Amgen has less capital equipment than it did in 2006 and spends only a fraction more on R&D....
...Although medical technology in the US is envied elsewhere, studies have shown it lagging behind other rich countries in terms of health outcomes....
...Such links are enhanced by the Oxford Bioscience Network, a not-for-profit group that provides purchasing and networking support for biotech and medical technology companies in Oxford and the south-east....
...Now two more Aim technology companies have succumbed to the lure of New York – Velti, the mobile marketing group, and CBay Systems, a specialist in medical transcriptions....
...This brief remark, first applied the isolation and purification of adrenalin, undergirds huge swaths of modern medical research....
International Edition